Oric Pharmaceuticals, Inc. ORIC
Biotechnology: Pharmaceutical Preparations · IPO 2020 · data as of November 13, 2026
Oric Pharmaceuticals, Inc. (ORIC) is a healthcare company listed in the US with a market value of about $815M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -33%.
About Oric Pharmaceuticals
Oric Pharmaceuticals is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2020. It was profitable in 0 of the last 8 years in our data. Its share count rose by 121% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 8 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Net income | -$129M | -$128M | -$101M | -$89M | -$79M | -$74M | -$27M | -$21M |
| Free cash flow | -$112M | -$114M | -$87M | -$77M | -$60M | -$46M | -$24M | -$21M |
| EPS (diluted) | $-1.47 | $-1.83 | $-1.96 | $-2.25 | $-2.07 | $-3.36 | $-14.15 | $-12.32 |
| Net margin | — | — | — | — | — | — | — | — |
| ROIC | -28.8% | -44.7% | -37.4% | -30.9% | -21.1% | -20.2% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 14 analysts is $21.71, 176% above the current price; targets range from $14.00 to $27.00; the consensus rating is “Strong buy”; expected EPS is $-1.49 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Oric Pharmaceuticals pay a dividend?
Not currently.
Is Oric Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. Oric Pharmaceuticals scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.